Skip to main content
Log in

MAQC and the era of genomic medicine

  • Comment
  • Published:

From Nature Biotechnology

View current issue Submit your manuscript

The MicroArray Quality Control consortium—a 16-year international effort led by the FDA and involving hundreds of scientists from academia, industry and government—helped make genomic medicine a reality.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1: The four project phases of the MAQC consortium (top) and advances in related genomic regulatory science (bottom).

References

  1. Tan, P. K. et al. Nucleic Acids Res. 31, 5676–5684 (2003).

    Article  CAS  Google Scholar 

  2. Taylor, J. K. Anal. Chem. 55, 600A–608A (1983).

    Article  CAS  Google Scholar 

  3. Zook, J. M. et al. Nat. Biotechnol. 37, 561–566 (2019).

    Article  CAS  Google Scholar 

  4. Critical Path Institute. Patient-Reported Outcome Consortium https://c-path.org/programs/proc/ (accessed 1 August 2021).

  5. Quantitative Imaging Biomarkers Alliance. https://www.rsna.org/research/quantitative-imaging-biomarkers-alliance (accessed 2 August 2021).

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Marc Salit.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Salit, M., Woodcock, J. MAQC and the era of genomic medicine. Nat Biotechnol 39, 1066–1067 (2021). https://doi.org/10.1038/s41587-021-01050-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41587-021-01050-y

  • Springer Nature America, Inc.

This article is cited by

Navigation